<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00836901</url>
  </required_header>
  <id_info>
    <org_study_id>30074</org_study_id>
    <nct_id>NCT00836901</nct_id>
  </id_info>
  <brief_title>Amoxicillin-Clavulanic Acid 400 mg-57 mg Chewable Tablets Under Non-Fasting Conditions</brief_title>
  <official_title>Randomized, 2-Way Crossover, Bioequivalence Study of Amoxicillin-Clavulanic Acid 400 mg-57 mg Chewable Tablets and AUGMENTIN® 400 mg-57 mg Chewable Tablets Administered as 1 x 400 mg-57 mg Chewable Tablet in Healthy Subjects Under Fed Conditions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Teva Pharmaceuticals USA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Teva Pharmaceuticals USA</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to compare the rate and extent of absorption of&#xD;
      amoxicillin-clavulanic acid 400 mg-57 mg chewable tablets (test) versus Augmentin®&#xD;
      (reference) administered as 1 x 400 mg-57 mg chewable tablet under fed conditions.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Criteria for Evaluation: FDA Bioequivalence Criteria&#xD;
&#xD;
      Statistical Methods: FDA bioequivalence statistical methods&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2003</start_date>
  <completion_date type="Actual">September 2003</completion_date>
  <primary_completion_date type="Actual">September 2003</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cmax (Maximum Observed Concentration) - Amoxicillin</measure>
    <time_frame>Blood samples collected over 10 hour period</time_frame>
    <description>Bioequivalence based on Cmax</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-inf - [Area Under the Concentration-time Curve From Time Zero to Infinity (Extrapolated)] - Amoxicillin</measure>
    <time_frame>Blood samples collected over 10 hour period</time_frame>
    <description>Bioequivalence based on AUC0-inf</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-t - [Area Under the Concentration-time Curve From Time Zero to Time of Last Non-zero Concentration (Per Participant)] - Amoxicillin</measure>
    <time_frame>Blood samples collected over 10 hour period</time_frame>
    <description>Bioequivalence based on AUC0-t</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax (Maximum Observed Concentration) - Clavulanic Acid</measure>
    <time_frame>Blood samples were collected over 10 hour period</time_frame>
    <description>Bioequivalence based on Cmax</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-inf [Area Under the Concentration-time Curve From Time Zero to Infinity (Extrapolated)] - Clavunlanic Acid</measure>
    <time_frame>Blood samples collected over 10 hour period</time_frame>
    <description>Bioequivalence based on AUC0-inf</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-t [Area Under the Concentration-time Curve From Time Zero to Time of Last Non-zero Concentration (Per Participant) - Clavulanic Acid</measure>
    <time_frame>Blood samples collected over 10 hour period</time_frame>
    <description>Bioequivalence based on AUC0-t</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">52</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Amoxicillin Calvulanic Acid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Amoxicillin Clavulanic Acid 400-57 mg Chewable Tablet (test) dosed in first period followed by Augmentin® 40-57 mg Chewable Tablet (reference) dosed in second period</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Augmentin®</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Augmentin® 400-57 mg Chewable Tablet (test) dosed in first period followed by Amoxicillin Clavulanic Acid 400-57 mg Chewable Tablet (reference) dosed in second period</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>amoxicillin-clavulanic acid</intervention_name>
    <description>400 mg-57 mg chewable tablet</description>
    <arm_group_label>Amoxicillin Calvulanic Acid</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Augmentin®</intervention_name>
    <description>400 mg-57 mg chewable tablet</description>
    <arm_group_label>Augmentin®</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
          -  Subjects will be females and/or males, non-smokers, 18 years of age and older.&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
          -  Clinically significant illnesses within 4 weeks of the administration of study&#xD;
             medication.&#xD;
&#xD;
          -  Clinically significant surgery within 4 weeks prior to the administration of the study&#xD;
             medication.&#xD;
&#xD;
          -  Any clinically significant abnormality found during medical screening.&#xD;
&#xD;
          -  Any reason which, in the opinion of the medical subinvestigator, would prevent the&#xD;
             subject from participating in the study.&#xD;
&#xD;
          -  Abnormal laboratory tests judged clinically significant.&#xD;
&#xD;
          -  Positive urine drug screen at screening.&#xD;
&#xD;
          -  Positive testing for hepatitis B, hepatitis C or HIV at screening.&#xD;
&#xD;
          -  ECG abnormalities (clinically significant) or vital sign abnormalities (systolic blood&#xD;
             pressure lower than 90 or over 140 mmHg, or diastolic blood pressure lower than 50 or&#xD;
             over 90; or heart rate less than 50 bpm) at screening.&#xD;
&#xD;
          -  Subjects with BMI ≥30.0.&#xD;
&#xD;
          -  History of significant alcohol abuse within six months of the screening visit or any&#xD;
             indication of the regular use of more than two units of alcohol per day (1 Unit = 150&#xD;
             mL of wine or 360 mL of beer or 45 mL of alcohol 40%).&#xD;
&#xD;
          -  History of drug abuse or use of illegal drugs: use of soft drugs (such as marijuana)&#xD;
             within 3 months of the screening visit or hard drugs (such as cocaine, phencyclidine&#xD;
             (PCP) and crack) within 1 year of the screening visit.&#xD;
&#xD;
          -  Any food allergy, intolerance, restriction or special diet that, in the opinion of the&#xD;
             medical subinvestigator, contraindicates the subject's participation in this study.&#xD;
&#xD;
          -  History of allergic or hypersensitivity reactions to amoxicillin or clavulanic acid or&#xD;
             other related drugs (e.g. penicillin, cephalosporins, cephamycins).&#xD;
&#xD;
          -  Use of any drugs known to induce or inhibit hepatic drug metabolism (examples of&#xD;
             inducers: barbiturates, carbamazepine, phenytoin, glucocorticoids, rifampin/rifabutin;&#xD;
             examples of inhibitors: antidepressants, cimetidine, diltiazem, erythromycin,&#xD;
             ketoconazole, MAO inhibitors, neuroleptics, verapamil, quinidine, valproic acid) use&#xD;
             of an investigational drug or participation on an investigation study within 30 days&#xD;
             prior to the administration of the study medication.&#xD;
&#xD;
          -  Clinically significant history or presence of any clinically significant&#xD;
             gastrointestinal pathology (e.g. chronic diarrhea, inflammatory bowel diseases),&#xD;
             unresolved gastrointestinal symptoms (e.g. diarrhea, vomiting), liver or kidney&#xD;
             disease, or other conditions known to interfere with the absorption, distribution,&#xD;
             metabolism, or excretion of the drug.&#xD;
&#xD;
          -  Any clinically significant history or presence of clinically significant neurological,&#xD;
             endocrinal, cardiovascular, pulmonary, hematologic, immunologic, psychiatric or&#xD;
             metabolic disease.&#xD;
&#xD;
          -  Any food allergy, intolerance, restriction or special diet that could, in the opinion&#xD;
             of the Medical Subinvestigator, contraindicate the subject's participation in this&#xD;
             study.&#xD;
&#xD;
          -  Use of prescription medication within 14 days prior to administration of study&#xD;
             medication or over-the-counter products )including natural products, vitamins, garlic&#xD;
             as a supplement) within 7 days prior to administration of study medication, except for&#xD;
             topical products without systemic absorption.&#xD;
&#xD;
          -  Subjects who have had a depot injection or an implant of any drug 3 months prior to&#xD;
             administration of study medication.&#xD;
&#xD;
          -  Donation of plasma (500 mL) within 7 days. Donation or loss of whole blood prior to&#xD;
             administration of the study medication as follows:&#xD;
&#xD;
               -  less than 300 mL of whole blood within 30 days, or&#xD;
&#xD;
               -  300 mL to 500 mL of whole blood within 45 days, or&#xD;
&#xD;
               -  more than 500 mL of whole blood within 56 days.&#xD;
&#xD;
          -  Positive alcohol breath test at screening.&#xD;
&#xD;
          -  Subjects who have used tobacco in any form within the 90 days preceding study drug&#xD;
             administration.&#xD;
&#xD;
          -  Intolerance to venipunctures.&#xD;
&#xD;
          -  Subjects with a clinically significant history of tuberculosis, epilepsy, asthma,&#xD;
             diabetes, psychosis, or glaucoma will not be eligible for this study.&#xD;
&#xD;
          -  Any history of known Augmentin-associated cholestatic jaundice/hepatic dysfunction&#xD;
&#xD;
          -  Any known active mononucleosis&#xD;
&#xD;
          -  Subjects with dentures or braces.&#xD;
&#xD;
        Additional exclusion criteria for female subjects only:&#xD;
&#xD;
          -  Breast feeding subjects.&#xD;
&#xD;
          -  Positive urine pregnancy test at screening (performed on all females).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Richard Larouche, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Anapharm</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Anapharm Inc.</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3X 2H9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>July 2009</verification_date>
  <study_first_submitted>February 2, 2009</study_first_submitted>
  <study_first_submitted_qc>February 3, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 4, 2009</study_first_posted>
  <results_first_submitted>May 7, 2009</results_first_submitted>
  <results_first_submitted_qc>July 6, 2009</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 18, 2009</results_first_posted>
  <last_update_submitted>July 6, 2009</last_update_submitted>
  <last_update_submitted_qc>July 6, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 18, 2009</last_update_posted>
  <keyword>Bioequivalence</keyword>
  <keyword>Healthy Subjects</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amoxicillin</mesh_term>
    <mesh_term>Amoxicillin-Potassium Clavulanate Combination</mesh_term>
    <mesh_term>Clavulanic Acids</mesh_term>
    <mesh_term>Clavulanic Acid</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Amoxicillin Clavulanic Acid (Test) First</title>
          <description>Amoxicillin-Clavulanic Acid 400/57 mg chewable tablet (test) dosed in first period followed by Augmentin® 400/57 mg chewable tablet (reference) dosed in second period</description>
        </group>
        <group group_id="P2">
          <title>Augmentin® (Reference) First</title>
          <description>Augmentin® 400/57 mg chewable tablet (reference) dosed in first period followed by Amoxicillin-Clavulanic Acid 400/57 mg chewable tablet (test) dosed in second period</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>First Intervention</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
                <participants group_id="P2" count="28"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="23"/>
                <participants group_id="P2" count="28"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Second Intervention</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="23"/>
                <participants group_id="P2" count="28"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="23"/>
                <participants group_id="P2" count="28"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Amoxicillin Clavulanic Acid (Test) First</title>
          <description>Amoxicillin-Clavulanic Acid 400/57 mg chewable tablet (test) dosed in first period followed by Augmentin® 400/57 mg chewable tablet (reference) dosed in second period</description>
        </group>
        <group group_id="B2">
          <title>Augmentin® (Reference) First</title>
          <description>Augmentin® 400/57 mg chewable tablet (reference) dosed in first period followed by Amoxicillin-Clavulanic Acid 400/57 mg chewable tablet (test) dosed in second period</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="24"/>
            <count group_id="B2" value="28"/>
            <count group_id="B3" value="52"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="28"/>
                    <measurement group_id="B3" value="52"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="36"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Caucasian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>American Hispanic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Canada</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="28"/>
                    <measurement group_id="B3" value="52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Cmax (Maximum Observed Concentration) - Amoxicillin</title>
        <description>Bioequivalence based on Cmax</description>
        <time_frame>Blood samples collected over 10 hour period</time_frame>
        <population>Data from all subjects who completed the study were included in the statistical analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Amoxicillin Clavulanic Acid</title>
            <description>Amoxicillin-Clavulanic Acid 400/57 mg chewable tablet (test) dosed in either period</description>
          </group>
          <group group_id="O2">
            <title>Augmentin®</title>
            <description>Augmentin® 400/57 mg chewable tablet (reference) dosed in either period</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax (Maximum Observed Concentration) - Amoxicillin</title>
          <description>Bioequivalence based on Cmax</description>
          <population>Data from all subjects who completed the study were included in the statistical analysis.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="51"/>
                <count group_id="O2" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4482.26" spread="1157.70"/>
                    <measurement group_id="O2" value="4549.67" spread="1116.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Using GLM procedures in SAS, analysis of variance (ANOVA)was performed on log-transformed AUC0-t, AUC0-inf and Cmax at the significance level of 0.05.</non_inferiority_desc>
            <param_type>Ratio of Least Squares Means</param_type>
            <param_value>97.70</param_value>
            <ci_percent>90</ci_percent>
            <ci_lower_limit>93.19</ci_lower_limit>
            <ci_upper_limit>102.43</ci_upper_limit>
            <estimate_desc>Bioequivalence is established when 90% Confidence Interval falls within 80 - 125</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUC0-inf - [Area Under the Concentration-time Curve From Time Zero to Infinity (Extrapolated)] - Amoxicillin</title>
        <description>Bioequivalence based on AUC0-inf</description>
        <time_frame>Blood samples collected over 10 hour period</time_frame>
        <population>Data from all subjects who completed the study were included in the statistical analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Amoxicillin Clavulanic Acid</title>
            <description>Amoxicillin-Clavulanic Acid 400/57 mg chewable tablet (test) dosed in either period</description>
          </group>
          <group group_id="O2">
            <title>Augmentin®</title>
            <description>Augmentin® 400/57 mg chewable tablet (reference) dosed in either period</description>
          </group>
        </group_list>
        <measure>
          <title>AUC0-inf - [Area Under the Concentration-time Curve From Time Zero to Infinity (Extrapolated)] - Amoxicillin</title>
          <description>Bioequivalence based on AUC0-inf</description>
          <population>Data from all subjects who completed the study were included in the statistical analysis.</population>
          <units>ng*h/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="51"/>
                <count group_id="O2" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19403.12" spread="4003.43"/>
                    <measurement group_id="O2" value="19518.22" spread="3573.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Using GLM procedures in SAS, analysis of variance (ANOVA)was performed on log-transformed AUC0-t, AUC0-inf and Cmax at the significance level of 0.05.</non_inferiority_desc>
            <param_type>Ratio of Least Squares Means</param_type>
            <param_value>99.28</param_value>
            <ci_percent>90</ci_percent>
            <ci_lower_limit>97.09</ci_lower_limit>
            <ci_upper_limit>101.53</ci_upper_limit>
            <estimate_desc>Bioequivalence is established when 90% Confidence Interval falls within 80 - 125</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUC0-t - [Area Under the Concentration-time Curve From Time Zero to Time of Last Non-zero Concentration (Per Participant)] - Amoxicillin</title>
        <description>Bioequivalence based on AUC0-t</description>
        <time_frame>Blood samples collected over 10 hour period</time_frame>
        <population>Data from all subjects who completed the study were included in the statistical analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Amoxicillin Clavulanic Acid</title>
            <description>Amoxicillin-Clavulanic Acid 400/57 mg chewable tablet (test) dosed in either period</description>
          </group>
          <group group_id="O2">
            <title>Augmentin®</title>
            <description>Augmentin® 400/57 mg chewable tablet (reference) dosed in either period</description>
          </group>
        </group_list>
        <measure>
          <title>AUC0-t - [Area Under the Concentration-time Curve From Time Zero to Time of Last Non-zero Concentration (Per Participant)] - Amoxicillin</title>
          <description>Bioequivalence based on AUC0-t</description>
          <population>Data from all subjects who completed the study were included in the statistical analysis</population>
          <units>ng*h/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="51"/>
                <count group_id="O2" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18299.44" spread="3147.95"/>
                    <measurement group_id="O2" value="18746.55" spread="3331.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Using GLM procedures in SAS, analysis of variance (ANOVA)was performed on log-transformed AUC0-t, AUC0-inf and Cmax at the significance level of 0.05.</non_inferiority_desc>
            <param_type>Ratio of Least Squares Means</param_type>
            <param_value>97.64</param_value>
            <ci_percent>90</ci_percent>
            <ci_lower_limit>96.12</ci_lower_limit>
            <ci_upper_limit>99.19</ci_upper_limit>
            <estimate_desc>Bioequivalence is established when 90% Confidence Interval falls within 80 - 125</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Cmax (Maximum Observed Concentration) - Clavulanic Acid</title>
        <description>Bioequivalence based on Cmax</description>
        <time_frame>Blood samples were collected over 10 hour period</time_frame>
        <population>Data from all subjects who completed the study were included in the statistical analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Amoxicillin Clavulanic Acid</title>
            <description>Amoxicillin-Clavulanic Acid 400/57 mg chewable tablet (test) dosed in either period</description>
          </group>
          <group group_id="O2">
            <title>Augmentin®</title>
            <description>Augmentin® 400/57 mg chewable tablet (reference) dosed in either period</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax (Maximum Observed Concentration) - Clavulanic Acid</title>
          <description>Bioequivalence based on Cmax</description>
          <population>Data from all subjects who completed the study were included in the statistical analysis</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="51"/>
                <count group_id="O2" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="734.20" spread="300.57"/>
                    <measurement group_id="O2" value="766.38" spread="299.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Using GLM procedures in SAS, analysis of variance (ANOVA)was performed on log-transformed AUC0-t, AUC0-inf and Cmax at the significance level of 0.05.</non_inferiority_desc>
            <param_type>Ratio of Least Squares Means</param_type>
            <param_value>94.59</param_value>
            <ci_percent>90</ci_percent>
            <ci_lower_limit>85.64</ci_lower_limit>
            <ci_upper_limit>104.47</ci_upper_limit>
            <estimate_desc>Bioequivalence is established when 90% Confidence Interval falls within 80 - 125</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUC0-inf [Area Under the Concentration-time Curve From Time Zero to Infinity (Extrapolated)] - Clavunlanic Acid</title>
        <description>Bioequivalence based on AUC0-inf</description>
        <time_frame>Blood samples collected over 10 hour period</time_frame>
        <population>Data from all subjects who completed the study were included in the statistical analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Amoxicillin Clavulanic Acid</title>
            <description>Amoxicillin-Clavulanic Acid 400/57 mg chewable tablet (test) dosed in either period</description>
          </group>
          <group group_id="O2">
            <title>Augmentin®</title>
            <description>Augmentin® 400/57 mg chewable tablet (reference) dosed in either period</description>
          </group>
        </group_list>
        <measure>
          <title>AUC0-inf [Area Under the Concentration-time Curve From Time Zero to Infinity (Extrapolated)] - Clavunlanic Acid</title>
          <description>Bioequivalence based on AUC0-inf</description>
          <population>Data from all subjects who completed the study were included in the statistical analysis</population>
          <units>ng*h/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="51"/>
                <count group_id="O2" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1772.85" spread="664.55"/>
                    <measurement group_id="O2" value="1864.33" spread="676.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Using GLM procedures in SAS, analysis of variance (ANOVA)was performed on log-transformed AUC0-t, AUC0-inf and Cmax at the significance level of 0.05.</non_inferiority_desc>
            <param_type>Ratio of Least Squares Means</param_type>
            <param_value>94.44</param_value>
            <ci_percent>90</ci_percent>
            <ci_lower_limit>87.83</ci_lower_limit>
            <ci_upper_limit>101.54</ci_upper_limit>
            <estimate_desc>Bioequivalence is established when 90% Confidence Interval falls within 80 - 125</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUC0-t [Area Under the Concentration-time Curve From Time Zero to Time of Last Non-zero Concentration (Per Participant) - Clavulanic Acid</title>
        <description>Bioequivalence based on AUC0-t</description>
        <time_frame>Blood samples collected over 10 hour period</time_frame>
        <population>Data from all subjects who completed the study were included in the statistical analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Amoxicillin Clavulanic Acid</title>
            <description>Amoxicillin-Clavulanic Acid 400/57 mg chewable tablet (test) dosed in either period</description>
          </group>
          <group group_id="O2">
            <title>Augmentin®</title>
            <description>Augmentin® 400/57 mg chewable tablet (reference) dosed in either period</description>
          </group>
        </group_list>
        <measure>
          <title>AUC0-t [Area Under the Concentration-time Curve From Time Zero to Time of Last Non-zero Concentration (Per Participant) - Clavulanic Acid</title>
          <description>Bioequivalence based on AUC0-t</description>
          <population>Data from all subjects who completed the study were included in the statistical analysis</population>
          <units>ng*h/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="51"/>
                <count group_id="O2" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1693.67" spread="654.95"/>
                    <measurement group_id="O2" value="1785.27" spread="661.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Using GLM procedures in SAS, analysis of variance (ANOVA)was performed on log-transformed AUC0-t, AUC0-inf and Cmax at the significance level of 0.05.</non_inferiority_desc>
            <param_type>Ratio of Least Squares Means</param_type>
            <param_value>94.08</param_value>
            <ci_percent>90</ci_percent>
            <ci_lower_limit>87.19</ci_lower_limit>
            <ci_upper_limit>101.52</ci_upper_limit>
            <estimate_desc>Bioequivalence is established when 90% Confidence Interval falls within 80 - 125</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Principal Investigator is not permitted to discuss or publish trial results.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Manager, Biopharmaceutics</name_or_title>
      <organization>Teva Pharmaceuticals USA</organization>
      <phone>1-866-384-5525</phone>
      <email>clinicaltrialqueries@tevausa.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

